» Articles » PMID: 26107230

The Level of Squamous Cell Carcinoma Antigen and Lymph Node Metastasis in Locally Advanced Cervical Cancer

Overview
Specialty Oncology
Date 2015 Jun 25
PMID 26107230
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study aimed to determine the utility and a cut-off level of serum squamous cell carcinoma antigen (SCC-Ag) to predict lymph node metastasis in locally advanced cervical cancer cases. We also investigated the correlation between SCC-Ag level and lymph node status.

Materials And Methods: From June 2009 to June 2014, 232 patients with cervical cancer stage IB2-IVA, who were treated at Ramathibodi Hospital, were recruited. Receiver operating characteristic (ROC) curves were used to identify the best cut-off point of SCC-Ag level to predict lymph node metastasis. Quantile regression was performed to evaluate the correlation between SCC-Ag levels and pelvic lymph node metastasis, paraaortic lymph node metastasis, and parametrial involvement as well as tumor size.

Results: Pelvic lymph node metastasis and paraaortic lymph node metastasis were diagnosed in 46.6% and 20.1% of the patients, respectively. The median SCC-Ag level was 6 ng/mL (range, 0.5 to 464.6 ng/ mL). The areas under ROC curves between SCC-Ag level and pelvic lymph node metastasis, paraaotic lymph node metastasis, parametrial involvements were low. SCC-Ag level was significantly correlated with paraaortic lymph node status (p=0.045) but not with pelvic lymph node status and parametrial involvement. SCC-Ag level was also related to the tumor diameter (p<0.05).

Conclusions: SCC-Ag level is not a good predictor for pelvic and paraaortic lymph node metastasis. However, it is still beneficial to assess the tumor burden of squamous cell carcinoma of the cervix.

Citing Articles

Clinical utility of pretreatment serum squamous cell carcinoma antigen for prognostication and decision-making in patients with early-stage cervical cancer.

Huang X, Huo L, Luo Y, Chen K, Li J, Shi L Ther Adv Med Oncol. 2023; 15:17588359231165974.

PMID: 37025259 PMC: 10071156. DOI: 10.1177/17588359231165974.


Prognostic factors for IB2-IIIB cervical cancer patients treated by radiation therapy with high-dose-rate brachytherapy in a single-institution study.

Xiu Y, Meng F, Wang Z, Zhao K, Wang Y, Chen Z J Contemp Brachytherapy. 2022; 14(4):332-340.

PMID: 36199952 PMC: 9528829. DOI: 10.5114/jcb.2022.118674.


Squamous Cell Carcinoma Antigen: Clinical Application and Research Status.

Zhu H Diagnostics (Basel). 2022; 12(5).

PMID: 35626221 PMC: 9139199. DOI: 10.3390/diagnostics12051065.


Assessment of retroperitoneal lymph node status in locally advanced cervical cancer.

Li W, Xiong L, Zhu Q, Lu H, Zhong M, Liang M BMC Cancer. 2021; 21(1):484.

PMID: 33933005 PMC: 8088051. DOI: 10.1186/s12885-021-08208-6.


The Adler grade by Doppler ultrasound is associated with clinical pathology of cervical cancer: Implication for clinical management.

Che D, Yang Z, Wei H, Wang X, Gao J PLoS One. 2020; 15(8):e0236725.

PMID: 32777812 PMC: 7417192. DOI: 10.1371/journal.pone.0236725.